• 1. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Naphthyridine carboxylic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Naphthyridines Naphthyridine carboxylic acids and derivatives

Research Brief on tert-Butyl 2-Cyano-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate (CAS: 259809-46-6)

In recent years, the compound tert-Butyl 2-Cyano-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate (CAS: 259809-46-6) has garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, characterized by its naphthyridine core and cyano functional group, has emerged as a versatile intermediate in the synthesis of bioactive molecules, particularly in the development of kinase inhibitors and other therapeutic agents. The unique structural features of this compound make it a valuable scaffold for medicinal chemistry applications, enabling the exploration of novel drug candidates with potential applications in oncology, neurology, and infectious diseases.

Recent studies have focused on optimizing the synthetic routes for tert-Butyl 2-Cyano-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate to improve yield and purity. A 2023 publication in the Journal of Medicinal Chemistry reported a streamlined, high-yield synthesis utilizing palladium-catalyzed cross-coupling reactions, which significantly reduced the number of steps compared to traditional methods. This advancement has facilitated broader access to the compound for research purposes, enabling more extensive structure-activity relationship (SAR) studies. The improved synthetic protocol also addresses previous challenges related to scalability, making it more feasible for industrial applications.

The pharmacological potential of derivatives based on the tert-Butyl 2-Cyano-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate scaffold has been a major focus of recent investigations. A 2024 study published in Bioorganic & Medicinal Chemistry Letters demonstrated that modifications at the 2-cyano and 6-carboxylate positions could yield compounds with potent inhibitory activity against cyclin-dependent kinases (CDKs), particularly CDK4 and CDK6. These kinases play critical roles in cell cycle regulation, and their dysregulation is implicated in various cancers. The study highlighted that specific derivatives exhibited nanomolar IC50 values, along with favorable selectivity profiles, suggesting their potential as lead compounds for anticancer drug development.

In addition to its applications in oncology, tert-Butyl 2-Cyano-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate has shown promise in the development of central nervous system (CNS) therapeutics. A recent preclinical study explored its derivatives as modulators of neurotransmitter receptors, particularly those involved in neurodegenerative diseases such as Alzheimer's and Parkinson's. The findings, published in ACS Chemical Neuroscience, indicated that certain analogs could cross the blood-brain barrier and exhibit neuroprotective effects in vitro and in vivo. These results underscore the compound's versatility and its potential to address unmet medical needs in neurology.

Despite these promising developments, challenges remain in the clinical translation of tert-Butyl 2-Cyano-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate-based therapeutics. Issues such as metabolic stability, toxicity profiles, and formulation optimization require further investigation. However, ongoing research efforts, including computational modeling and high-throughput screening, are expected to accelerate the identification of optimal derivatives with enhanced pharmacokinetic and pharmacodynamic properties. The compound's growing prominence in drug discovery pipelines highlights its enduring relevance in the field of chemical biology and pharmaceutical sciences.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)